What guidance did Bristol-Myers Squibb's management provide for the next earnings period?

What is Bristol-Myers Squibb's gross profit margin?

What is the market's earnings forecast for Bristol-Myers Squibb next quarter?

What is Bristol-Myers Squibb's latest dividend and current dividend yield?

What were the key takeaways from Bristol-Myers Squibb’s earnings call?

What were the key takeaways from Bristol-Myers Squibb's earnings call?

Did Bristol-Myers Squibb beat or miss consensus estimates last quarter?

What does Bristol-Myers Squibb do and what are its main business segments?

- **Growth Portfolio Dominance**: 2025 growth portfolio grew 17%, offsetting legacy decline. Q4 growth portfolio revenue $7.4 billion (15% YoY).
- **Pipeline Catalysts**: 6 Phase III readouts in 2026, including milvexian (AFib) and admilparant (IPF/PPF). 2026-2030 pipeline includes 30+ launch opportunities.
- **Eliquis Strategy**: 2026 growth 10%-15% driven by pricing reforms; 2027 step-down of $1.5-$2 billion due to OUS generics.
- **Financial Strength**: 2026 EPS guidance $6.05-$6.35, supported by $16.3 billion operating expenses and 18% tax rate.
- **Commercial Momentum**: Breyanzi Q4 revenue +47%, Reblozyl +21%; Cobenfy TRx surpasses 100,000 in first year.

**【CEO Summary Section】**
- **Revenue Growth**: Full-year 2025 growth portfolio revenue grew 17%, offsetting a $4 billion decline in legacy products. Q4 growth portfolio revenue increased 15% to $7.4 billion, accounting for 60% of total revenue.
- **Product Highlights**: Opdualag, Breyanzi, Camzyos, and Reblozyl each exceeded $1 billion in annual sales. Breyanzi revenue grew 47% in Q4, driven by demand across approved indications.
- **Pipeline Momentum**: 6 Phase III readouts expected in 2026, including milvexian (AFib), admilparant (IPF/PPF), and iberdomide (multiple myeloma). 2026-2030 pipeline includes over 30 launch opportunities.
- **2026 Guidance**: Revenue $46-$47.5 billion, EPS $6.05-$6.35, with Eliquis growth 10%-15% and legacy portfolio decline 12%-16%.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: Total revenue $12.5 billion (flat YoY). Gross margin 71.9%, down 210bps due to product mix. Operating expenses decreased $1.2 billion YoY, with $1 billion cost savings achieved in 2025.
- **2026 Outlook**: Gross margin 69%-70%, operating expenses $16.3 billion (down from $16.6 billion in 2025). Tax rate 18%, EPS guidance $6.05-$6.35.
- **Cash Flow**: Generated $2 billion in Q4 2025, with $11 billion in cash equivalents and marketable securities.

**【Q&A Highlights】**
- **Eliquis Pricing**: 40% WACC reduction eliminates inflation penalties, driving 10%-15% growth in 2026. 2027 step-down of $1.5-$2 billion due to OUS generic competition.
- **Pipeline Confidence**: Milvexian (AFib) Phase III readout expected in Q4 2026; admilparant (IPF/PPF) Phase III data in H2 2026. CELMoD programs (iberdomide, mezigdomide) positioned for community oncology adoption.
- **Commercial Execution**: Cobenfy TRx surpasses 100,000 in first year; Qvantig launch progressing with 30%-40% IV-to-subQ conversion target by 2028.
- **Business Development**: Focus on therapeutic area depth (oncology, cardiovascular, immunology) with $2 billion cost savings enabling reinvestment in growth.


Bristol-Myers Squibb Company (BMY) Q4 2025 Earnings Call Transcript

- **Topline Growth**: Q3 revenue up 17% in growth portfolio, driven by oncology and cardiovascular assets. Full-year guidance raised to $47.5-$48B.
- **Pipeline Breakthroughs**: iberdomide Phase III success in multiple myeloma; pumitamig advancing in 14 solid tumor studies.
- **Cost Efficiency**: $1B savings achieved; $2B target by 2027. EPS guidance narrowed to $6.40-$6.60, reflecting disciplined financial management.
- **Strategic Moves**: Orbital Therapeutics acquisition strengthens cell therapy pipeline; AI integration to enhance R&D and commercial execution.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 revenue of $12.2 billion reflects 17% year-over-year growth in the growth portfolio, driven by Opdivo, Reblozyl, Breyanzi, and Camzyos. Full-year guidance raised by $750 million to $47.5-$48 billion.
- **Pipeline Momentum**: Phase III EXCALIBER study for iberdomide in multiple myeloma met MRD negativity endpoint. Pumitamig (PD-1/VEGF bispecific) advancing in NSCLC, SCLC, and TNBC. CD19 NEX-T cell therapy shows promise in autoimmune diseases.
- **Strategic Initiatives**: $1 billion in cost savings achieved; $2 billion target by 2027. Orbital Therapeutics acquisition bolsters cell therapy franchise. AI integration to enhance operational efficiency.

**【CFO Financial Commentary】**
- **Sales Performance**: 
  - Opdivo/Qvantig: $2.5B (+6%), tracking for high-single to low-double-digit 2025 growth.
  - Reblozyl: $615M (+38% U.S.), annualizing >$2B.
  - Camzyos: $296M (+88%), annualizing >$1B.
  - Eliquis: $3.7B (+23%), benefiting from Medicare redesign.
- **Financial Metrics**: 
  - Gross margin: 73% (product mix driven).
  - Operating expenses: $4.2B (-$100M vs. 2024Q3), reflecting $1B+ savings year-to-date.
  - EPS guidance narrowed to $6.40-$6.60 (midpoint unchanged) due to $0.20 EPS impact from in-process R&D charges.

**【Q&A Highlights】**
- **Cobenfy**: Steady growth with $43M Q3 sales, targeting schizophrenia and Alzheimer's psychosis. ADEPT-2 data expected by end-2025; 2 additional AD studies in 2026.
- **Pumitamig**: BioNTech partnership progressing 14 studies, including first-line NSCLC, SCLC, and TNBC. Potential to be first-in-class in MSS CRC.
- **Milvexian**: Phase III trials in AF, ACS, and SSP expected to read out in 2026. BID dosing may offer efficacy advantage vs. competitors.
- **Policy Updates**: Engaging with administration on drug pricing; Eliquis DTC program launched at 40% discount. IRA negotiations for Pomalyst conclude Nov 30, with no impact on 2026 outlook.


Bristol-Myers Squibb Company (BMY) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 revenue $12.3B, with growth portfolio up 17% YoY. Full-year guidance raised to $46.5B-$47.5B. 
- **Strategic Deals**: BioNTech partnership for BNT327 (IO bispecific), Philochem collaboration for prostate cancer radiopharmaceutical. 
- **Pipeline Strength**: 7 registration-stage assets, including milvexian (stroke/ACS), BNT327 (IO), and Iza-bren (ADC). 
- **Cost Efficiency**: $260M YoY operating expense reduction, targeting $2B savings by 2027. 
- **Cobenfy Momentum**: 45K TRxs since launch, tracking ahead of schizophrenia benchmarks. 
- **Margin Outlook**: Gross margin expected to improve post-2028 Eliquis genericization. 


**【CEO Summary Section】**
- **Q2 Performance**: Total revenue of $12.3B, with the growth portfolio up 17% YoY, driven by oncology, hematology, and cardiovascular products. Key contributors include Opdivo ($2.6B), Qvantig ($30M), Reblozyl ($568M), Breyanzi ($344M), and Camzyos ($260M). 
- **Strategic Partnerships**: Announced a global partnership with BioNTech for BNT327 (PD-L1/VEGF bispecific) and a collaboration with Philochem for OncoACP3, a radiopharmaceutical for prostate cancer. Also formed a new company with Bain Capital to advance 5 immunology assets. 
- **Pipeline Momentum**: 7 registration-stage assets and 7 life-cycle management opportunities expected over the next 12-24 months. Notable programs include milvexian (secondary stroke prevention, ACS), admilparant (IPF), and Iza-bren (EGFR/HER3 ADC). 
- **Cost Optimization**: $1.5B strategic productivity initiative completed in 2024, with an additional $2B target by 2027. Operating expenses reduced by $260M in Q2, supporting margin expansion. 
- **Guidance Update**: Full-year revenue raised to $46.5B-$47.5B (midpoint +$700M), driven by growth portfolio strength and legacy portfolio outperformance. Non-GAAP EPS projected at $6.35-$6.65, excluding $0.57 charge for the BioNTech deal. 

**【CFO Financial Commentary】**
- **Revenue Breakdown**: 
  - **Oncology**: Opdivo up 7% in the U.S. (MSI-high CRC launch) and 7% ex-U.S. Qvantig contributed $30M in Q2. 
  - **Hematology**: Reblozyl (+46% ex-U.S.), Breyanzi (+122% globally). 
  - **Cardiovascular**: Camzyos (+86%), Eliquis (+6%). 
  - **Immunology**: Sotyktu (+29%), Cobenfy ($35M in Q2). 
- **P&L**: Gross margin 73%, operating expenses down $260M YoY. Diluted EPS $1.46, including $0.57 charge for BioNTech. 
- **Balance Sheet**: $13.9B cash, generating $3.9B in Q2. Targeting $10B debt reduction by mid-2026. 

**【Q&A Highlights】**
- **Pipeline Execution**: Emphasis on 7 registration-stage assets, including milvexian (stroke/ACS), BNT327 (IO), and Iza-bren (ADC). Management confident in pipeline derisking and commercial timing. 
- **Cobenfy Launch**: Tracking ahead of schizophrenia launch benchmarks, with 45K TRxs since launch. Focus on Medicare access, hospital penetration, and Phase IV switch study. 
- **Camzyos Competition**: Confident in leadership despite aficamten's REMS simplification, citing Camzyos' efficacy/safety profile and real-world data. 
- **Cost Management**: $2B productivity savings by 2027 will fund growth, with gross margin improvement expected post-2028 Eliquis genericization. 
- **Policy & IP**: Advocating for strong IP protections amid industry challenges, with a focus on maintaining R&D incentives. 


Bristol-Myers Squibb Company (BMY) Q2 2025 Earnings Call Transcript

- **Revenue Beat**: Q1 2025 revenue $11.2B (+18% growth in key products like Opdivo, Breyanzi, Camzyos).
- **Cobenfy Launch Success**: $27M in first quarter, TRx growth ahead of benchmarks despite adjunctive trial miss.
- **Cost Savings**: $500M OpEx savings in Q1; $2B+ annual savings by 2027.
- **Pipeline Progress**: Milvexian AF trial enrollment complete (2027 readout); seven Cobenfy Phase 3 trials launching in 2025.
- **Financial Strength**: $12.1B cash; $6.70-7.00 EPS guidance raise; 37% operating margin target.
- **Risk Management**: Navigating tariffs, FDA changes while maintaining execution discipline.


**【CEO Summary Section】**
- **Q1 2025 Performance**: Total revenue of $11.2 billion, driven by 18% growth in the growth portfolio (Opdivo, Breyanzi, Reblozyl, Camzyos). Cobenfy launched successfully with $27 million in Q1 sales.
- **Pipeline Updates**: 
  - Opdivo Qvantig (subcutaneous nivolumab) launched in Q1 with early adoption.
  - Breyanzi approved in the EU for follicular lymphoma.
  - Camzyos approved in Japan and updated US label reducing echo monitoring.
  - Milvexian (EGFRxHER3 ADC) enrollment complete for the LIBREXIA AF trial (2027 readout).
- **Challenges**: Camzyos failed to meet primary endpoint in non-obstructive HCM (ODYSSEY trial), but focus remains on obstructive HCM indication. Cobenfy missed adjunctive schizophrenia endpoint (ARISE trial), but monotherapy remains 70-80% of market.
- **Strategic Priorities**: 
  - $2 billion cost savings by 2027 (on track for $1 billion in 2025).
  - Business development as top capital allocation priority.
  - Navigating macro risks (tariffs, FDA changes) while maintaining execution discipline.

**【CFO Financial Commentary】**
- **Q1 2025 Financials**: 
  - GAAP net income: $420 million; Non-GAAP EPS: $1.80 (vs. $1.65 guidance midpoint).
  - Operating expenses down $500M YoY due to productivity initiatives.
  - Gross margin: 73% (product mix driven).
- **Updated Guidance**: 
  - Full-year revenue: $45.8-46.8 billion (up from $45-46.5B prior range).
  - Non-GAAP EPS: $6.70-7.00 (up $0.15 midpoint).
  - Operating margin target: 37%.
  - $2 billion debt reduction plan on track.
- **Key Drivers**: 
  - Growth portfolio outperformance (Cobenfy, Camzyos, Breyanzi).
  - Legacy portfolio decline moderating (Revlimid Q1 sales at top of $2-2.5B guidance range).
  - FX tailwind of ~$500M vs. prior guidance.

**【Q&A Key Themes】**
1. **Tariffs & Supply Chain**: 
  - US manufacturing already significant; evaluating pharma-specific tariffs.
  - $27M in Q1 tariffs impact; 2025 guidance includes ~$500M FX benefit.
  - Strategic productivity initiative to offset costs.
2. **Cobenfy Commercial Strategy**: 
  - Adjunctive failure no impact on monotherapy focus (70-80% market share).
  - Q1 TRx growth ahead of schizophrenia launch benchmarks.
  - 2025 gross-to-net ~35-40% (stable vs. prior expectations).
3. **Pipeline Readouts**: 
  - Milvexian AF trial on track for 2027 readout.
  - Seven Cobenfy Phase 3 trials launching in 2025 (Alzheimer's psychosis, agitation, cognition).
  - Iza-bren (EGFRxHER3 ADC) pivotal trial in TNBC starting Q2.
4. **Business Development**: 
  - Top priority with $12.1B cash and $2B+ annual savings.
  - Focus on strategic fits in core TAs (oncology, HCM, schizophrenia).
  - No gating factors on M&A pipeline.

**【Operational Highlights】**
- **Cost Optimization**: 
  - $500M OpEx savings in Q1 vs. prior year.
  - $1B+ savings on track for 2025 (total $2B by 2027).
- **Cash Flow**: 
  - Q1 operating cash flow: $2B.
  - $10B debt reduction plan on track.
  - 93rd consecutive dividend payment.
- **Pipeline Momentum**: 
  - 10+ new molecular entities expected by end-decade.
  - 30+ new indications in development.


Bristol-Myers Squibb (BMY)-24 Apr 25-2025 Q1 Earnings call transcript

- **Revenue Growth**: 2024 growth portfolio up 23%, driven by Reblozyl, Krazati, and Opdivo. 2025 guidance of $45.5 billion reflects generics impact but maintains growth momentum.
- **Cost Efficiency**: $1.1 billion in savings achieved, with $2 billion program by 2027 to enhance R&D and operational efficiency.
- **Pipeline Momentum**: 15+ registrational trials in 2025, including CEMZIOS (non-obstructive HCM) and ibertamide (multiple myeloma), with potential 10+ new medicines by 2030.
- **Cobenfy Potential**: Schizophrenia launch with 1,000+ TRx/week, expanding into Alzheimer's and bipolar with Phase III trials in 2025.
- **Eliquis Outlook**: 2025 growth tempered by Part D redesign but long-term benefit from coverage gap elimination.

**【CEO Summary Section】**
- **2024 Yearly Performance**: Delivered strong growth with the portfolio achieving double-digit revenue growth, driven by products like Reblozyl, Krazati, and Opdivo. The U.S. launch of Con (schizophrenia) and Opdivo Quvantic (subcutaneous nivolumab) marked significant milestones.
- **Operational Excellence**: Achieved $1.1 billion in cost savings toward the $1.5 billion target, with $400 million expected in 2025. An additional $2 billion in savings by 2027 will focus on R&D productivity and organizational efficiency.
- **Pipeline Acceleration**: Late-stage assets like CEMZIOS (non-obstructive HCM), Cobenfy (schizophrenia), and ibertamide (multiple myeloma) saw accelerated timelines, with key readouts in 2025.
- **2025 Guidance**: Revenue of $45.5 billion, reflecting generic impacts and growth portfolio strength. Non-GAAP EPS of $6.55–$6.85, supported by cost savings and disciplined investment.

**【CFO Financial Commentary】**
- **Q4 2024 Results**: Revenue of $12.3 billion (+9% YoY), with the growth portfolio up 23%. Gross margin declined 240bps due to product mix, but operating expenses grew 8% on R&D investments.
- **Cost Management**: $1.1 billion in savings realized, targeting $16 billion in 2025 operating expenses. Expanded savings program to $2 billion by 2027 will drop to the bottom line.
- **Cash Flow**: Generated $4.4 billion in Q4, supporting debt repayment and dividend continuity (93rd consecutive year).
- **Product Highlights**: Eliquis (+19% U.S. sales), Reblozyl (+70% growth), and BrionZ (+123% sales) drove performance. Covent launched with $10 million in Q4 sales, showing early prescription uptake.

**【Q&A Key Themes】**
- **Cobenfy (Cobintian)**: Strong launch with 1,000+ TRx/week, targeting 70%+ Medicaid/Medicare access. Phase III studies in Alzheimer's, bipolar, and autism to begin in 2025.
- **Eliquis Impact**: Medicare Part D redesign to reduce coverage gap, but Q1 2025 sales lower due to sequential destocking. Second-half growth expected.
- **Pipeline Catalysts**: 15+ registrational trials in 2025, including CEMZIOS (non-obstructive HCM), ibertamide (multiple myeloma), and Arlocell (CAR-T).
- **Business Development**: Focus on high-impact assets like Karuna (Cobenfy) to accelerate growth. No immediate plans for additional deals beyond pipeline investments.
- **Long-Term Growth**: Target top-tier sustainable growth by 2030, with 10+ new medicines and 30+ indication expansions over five years.

BMY

BMY fundamentals

Earnings Call

You can ask Aime